HC Wainwright Reaffirms Buy Rating for Oric Pharmaceuticals (NASDAQ:ORIC)

Oric Pharmaceuticals (NASDAQ:ORIC)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $25.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 181.21% from the company’s previous close.

Several other research firms have also recently weighed in on ORIC. Weiss Ratings restated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research report on Thursday, January 22nd. Wall Street Zen raised shares of Oric Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Cantor Fitzgerald reissued an “overweight” rating on shares of Oric Pharmaceuticals in a report on Monday, March 9th. Wedbush lowered their price objective on shares of Oric Pharmaceuticals from $20.00 to $17.00 and set an “outperform” rating on the stock in a research report on Wednesday. Finally, Oppenheimer restated an “outperform” rating and set a $15.00 price objective on shares of Oric Pharmaceuticals in a research report on Tuesday, February 24th. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Oric Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $19.90.

Oric Pharmaceuticals Price Performance

NASDAQ ORIC opened at $8.89 on Thursday. The company’s 50 day simple moving average is $11.50 and its two-hundred day simple moving average is $11.28. Oric Pharmaceuticals has a 1 year low of $3.90 and a 1 year high of $14.93. The stock has a market capitalization of $892.20 million, a PE ratio of -5.85 and a beta of 1.36.

Oric Pharmaceuticals (NASDAQ:ORIC) last released its quarterly earnings results on Monday, February 23rd. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.04. On average, research analysts anticipate that Oric Pharmaceuticals will post -2.17 EPS for the current year.

Insider Buying and Selling at Oric Pharmaceuticals

In other news, CFO Dominic Piscitelli sold 52,000 shares of Oric Pharmaceuticals stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $13.51, for a total value of $702,520.00. Following the sale, the chief financial officer directly owned 68,148 shares in the company, valued at approximately $920,679.48. This trade represents a 43.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 6.82% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ORIC. Federation des caisses Desjardins du Quebec raised its holdings in Oric Pharmaceuticals by 100.0% in the fourth quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company’s stock worth $33,000 after purchasing an additional 2,000 shares in the last quarter. Assetmark Inc. purchased a new position in Oric Pharmaceuticals during the third quarter valued at $37,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Oric Pharmaceuticals by 184.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,528 shares of the company’s stock valued at $37,000 after buying an additional 2,936 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Oric Pharmaceuticals by 26.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company’s stock worth $39,000 after buying an additional 977 shares during the period. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Oric Pharmaceuticals in the 3rd quarter worth about $60,000. Institutional investors own 95.05% of the company’s stock.

Oric Pharmaceuticals News Roundup

Here are the key news stories impacting Oric Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed a “buy” and set a $25 price target (large upside vs. current levels), providing a constructive analyst endorsement that can support longer-term upside. HC Wainwright Reaffirms Buy
• Positive Sentiment: Unusual options activity: traders bought ~2,266 call options (≈2,058% above normal), signaling short-term speculative bullish interest or hedging ahead of catalysts. (No article)
• Neutral Sentiment: Company granted inducement awards (80,000 stock options + 15,000 RSUs) to a new non‑executive employee — modest potential dilution but standard for new hires. Inducement Grants Filing
• Neutral Sentiment: Broader biotech headlines (e.g., BiopharmaDive roundup) are creating a mixed sector backdrop but are not ORIC‑specific drivers. Biotech News Roundup
• Negative Sentiment: ORIC shares fell sharply after early‑stage prostate cancer trial updates showed concerning side‑effect signals and prompted critical sell‑side commentary; multiple outlets report the move and investor selling. These clinical safety notes are the principal near‑term negative catalyst for the stock. Trial Data & Stock Drop
• Negative Sentiment: Analyst pressure: Wedbush lowered expectations for ORIC and subsequent coverage noted an analyst downgrade that coincided with a gap down in shares — further downward pressure from reduced sell‑side conviction. Wedbush Lowers Expectations Shares Gap Down After Downgrade

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.